Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2026)

Neurocrine Biosciences filings provide 9 years of Cost of Revenue readings, the most recent being $17.6 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 89.25% to $17.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $52.1 million, a 53.24% increase, with the full-year FY2025 number at $52.1 million, up 53.24% from a year prior.
  • Cost of Revenue hit $17.6 million in Q4 2025 for Neurocrine Biosciences, up from $14.0 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $17.6 million in Q4 2025 to a low of $2.9 million in Q1 2021.
  • Median Cost of Revenue over the past 5 years was $8.2 million (2023), compared with a mean of $8.2 million.
  • Biggest five-year swings in Cost of Revenue: surged 139.58% in 2023 and later fell 28.57% in 2024.
  • Neurocrine Biosciences' Cost of Revenue stood at $4.1 million in 2021, then surged by 87.8% to $7.7 million in 2022, then grew by 10.39% to $8.5 million in 2023, then increased by 9.41% to $9.3 million in 2024, then soared by 89.25% to $17.6 million in 2025.
  • The last three reported values for Cost of Revenue were $17.6 million (Q4 2025), $14.0 million (Q3 2025), and $11.3 million (Q2 2025) per Business Quant data.